Pharmakologisches Chaperon (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pharmakologisches Chaperon" in German language version.

refsWebsite

Global rank German rank

10nih.gov

4^th place

7^th place

9zdb-katalog.de

123^rd place

6^th place

7doi.org

2^nd place

3^rd place

2pfizer.de

low place

2aspetjournals.org

6,663^rd place

4,062^nd place

1laborjournal.de

low place

1mh-hannover.de

low place

1fu-berlin.de

3,329^th place

378^th place

1pharmazeutische-zeitung.de

8,614^th place

583^rd place

1uni-muenchen.de

3,337^th place

464^th place

1google.de

2,106^th place

139^th place

1clinicaltrials.gov

5,225^th place

2,461^st place

1news-medical.net

8,069^th place

low place

aspetjournals.org

pharmrev.aspetjournals.org

P. M. Conn, A. Ulloa-Aguirre u. a.: G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. In: Pharmacological reviews. Band 59, Nummer 3, September 2007, S. 225–250, ISSN 0031-6997. doi:10.1124/pr.59.3.2. PMID 17878512. (Review).

jpet.aspetjournals.org

S. Ishii, H. H. Chang u. a.: Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. In: Journal of pharmacology and experimental therapeutics. Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170.

clinicaltrials.gov

Klinische Studie (Phase III): Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease bei Clinicaltrials.gov der NIH

doi.org

P. M. Conn, A. Ulloa-Aguirre u. a.: G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. In: Pharmacological reviews. Band 59, Nummer 3, September 2007, S. 225–250, ISSN 0031-6997. doi:10.1124/pr.59.3.2. PMID 17878512. (Review).
S. Ishii, H. H. Chang u. a.: Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. In: Journal of pharmacology and experimental therapeutics. Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170.
R. Hamanaka, T. Shinohara u. a.: Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. In: Biochimica et biophysica acta. Band 1782, Nummer 6, Juni 2008, S. 408–413, ISSN 0006-3002. doi:10.1016/j.bbadis.2008.03.001. PMID 18381081.
S. W. Gersting, M. Staudigl u. a.: Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. In: The Journal of biological chemistry. Band 285, Nummer 40, Oktober 2010, S. 30686–30697, ISSN 1083-351X. doi:10.1074/jbc.M110.124016. PMID 20667834. PMC 2945563 (freier Volltext).
G. Andreotti, M. R. Guarracino u. a.: Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 36, ISSN 1750-1172. doi:10.1186/1750-1172-5-36. PMID 21138548. PMC 3016270 (freier Volltext). (Open Access).
R. Khanna, R. Soska u. a.: The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. In: Molecular therapy. Band 18, Nummer 1, Januar 2010, S. 23–33, ISSN 1525-0024. doi:10.1038/mt.2009.220. PMID 19773742. PMC 2839206 (freier Volltext).
Teresa Coelho, Giampaolo Merlini, Christine E Bulawa, James A Fleming, Daniel P Judge, Jeffery W Kelly, Mathew S Maurer, Violaine Planté-Bordeneuve, Richard Labaudinière, Rajiv Mundayat, Steve Riley, Ilise Lombardo, Pedro Huertas: Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. In: Neurol Ther. Band 5, Nr. 1, 2016, S. 1–25, doi:10.1007/s40120-016-0040-x, PMID 26894299, PMC 4919130 (freier Volltext).

fu-berlin.de

diss.fu-berlin.de

S. Vogelbein: Das Qualitätskontrollsystem in post-ER Kompartimenten eukaryotischer Zellen am Beispiel des Vasopressin-V2-Rezeptors. Dissertation, FU Berlin 2009, S. 21.

google.de

books.google.de

S. Biastoff, B. Dräger: Calystegines. In: G. A. Cordell (Hrsg.): The Alkaloids: Chemistry and Biology. S. 91. eingeschränkte Vorschau in der Google-Buchsuche

laborjournal.de

G. Sposny: Pharmacoperone. In: Laborjournal. Ausgabe 1, 2003.

mh-hannover.de

D. Manstein: Forschungsbericht 2009. (PDF; 110 kB) Institut für Biophysikalische Chemie, S. 33.

news-medical.net

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease. In: news-medical.net Vom 7. Mai 2010

nih.gov

ncbi.nlm.nih.gov

P. M. Conn, A. Ulloa-Aguirre u. a.: G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. In: Pharmacological reviews. Band 59, Nummer 3, September 2007, S. 225–250, ISSN 0031-6997. doi:10.1124/pr.59.3.2. PMID 17878512. (Review).
S. Ishii, H. H. Chang u. a.: Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. In: Journal of pharmacology and experimental therapeutics. Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170.
R. Hamanaka, T. Shinohara u. a.: Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. In: Biochimica et biophysica acta. Band 1782, Nummer 6, Juni 2008, S. 408–413, ISSN 0006-3002. doi:10.1016/j.bbadis.2008.03.001. PMID 18381081.
T. Arakawa, Y. Kita u. a.: Aggregation suppression of proteins by arginine during thermal unfolding. In: Protein and peptide letters. Band 13, Nummer 9, 2006, S. 921–927, ISSN 0929-8665. PMID 17100648.
S. W. Gersting, M. Staudigl u. a.: Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. In: The Journal of biological chemistry. Band 285, Nummer 40, Oktober 2010, S. 30686–30697, ISSN 1083-351X. doi:10.1074/jbc.M110.124016. PMID 20667834. PMC 2945563 (freier Volltext).
N. Asano, S. Ishii u. a.: In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. In: European Journal of Biochemistry. Band 267, Nummer 13, Juli 2000, S. 4179–4186, ISSN 0014-2956. PMID 10866822.
G. Andreotti, M. R. Guarracino u. a.: Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 36, ISSN 1750-1172. doi:10.1186/1750-1172-5-36. PMID 21138548. PMC 3016270 (freier Volltext). (Open Access).
R. Khanna, R. Soska u. a.: The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. In: Molecular therapy. Band 18, Nummer 1, Januar 2010, S. 23–33, ISSN 1525-0024. doi:10.1038/mt.2009.220. PMID 19773742. PMC 2839206 (freier Volltext).
Teresa Coelho, Giampaolo Merlini, Christine E Bulawa, James A Fleming, Daniel P Judge, Jeffery W Kelly, Mathew S Maurer, Violaine Planté-Bordeneuve, Richard Labaudinière, Rajiv Mundayat, Steve Riley, Ilise Lombardo, Pedro Huertas: Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. In: Neurol Ther. Band 5, Nr. 1, 2016, S. 1–25, doi:10.1007/s40120-016-0040-x, PMID 26894299, PMC 4919130 (freier Volltext).
S. K. Dash: Future targeted disease modifying drugs for Alzheimer's disease. In: Recent patents on CNS drug discovery. Band 6, Nummer 1, Januar 2011, S. 65–76, ISSN 1574-8898. PMID 21073430. (Review).

pfizer.de

Fachinformation Tafamidis-Meglumin 20 mg Weichkapseln, Stand Oktober 2020. Abgerufen am 2. Juni 2021.
Fachinformation Tafamidis 61 mg Weichkapseln, Stand Oktober 2020. Abgerufen am 2. Juni 2021.

pharmazeutische-zeitung.de

B. Wick-Urban: Trotz Ketonurie normal essen. In: Pharmazeutische Zeitung Online 15, 2007.

uni-muenchen.de

klinikum.uni-muenchen.de

LMU München: Molekulare Pädiatrie – Genetische Erkrankungen mit Proteinfaltung. Abgerufen am 14. Oktober 2011.

zdb-katalog.de

P. M. Conn, A. Ulloa-Aguirre u. a.: G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. In: Pharmacological reviews. Band 59, Nummer 3, September 2007, S. 225–250, ISSN 0031-6997. doi:10.1124/pr.59.3.2. PMID 17878512. (Review).
S. Ishii, H. H. Chang u. a.: Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. In: Journal of pharmacology and experimental therapeutics. Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170.
R. Hamanaka, T. Shinohara u. a.: Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. In: Biochimica et biophysica acta. Band 1782, Nummer 6, Juni 2008, S. 408–413, ISSN 0006-3002. doi:10.1016/j.bbadis.2008.03.001. PMID 18381081.
T. Arakawa, Y. Kita u. a.: Aggregation suppression of proteins by arginine during thermal unfolding. In: Protein and peptide letters. Band 13, Nummer 9, 2006, S. 921–927, ISSN 0929-8665. PMID 17100648.
S. W. Gersting, M. Staudigl u. a.: Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. In: The Journal of biological chemistry. Band 285, Nummer 40, Oktober 2010, S. 30686–30697, ISSN 1083-351X. doi:10.1074/jbc.M110.124016. PMID 20667834. PMC 2945563 (freier Volltext).
N. Asano, S. Ishii u. a.: In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. In: European Journal of Biochemistry. Band 267, Nummer 13, Juli 2000, S. 4179–4186, ISSN 0014-2956. PMID 10866822.
G. Andreotti, M. R. Guarracino u. a.: Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. In: Orphanet Journal of Rare Diseases. Band 5, 2010, S. 36, ISSN 1750-1172. doi:10.1186/1750-1172-5-36. PMID 21138548. PMC 3016270 (freier Volltext). (Open Access).
R. Khanna, R. Soska u. a.: The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. In: Molecular therapy. Band 18, Nummer 1, Januar 2010, S. 23–33, ISSN 1525-0024. doi:10.1038/mt.2009.220. PMID 19773742. PMC 2839206 (freier Volltext).
S. K. Dash: Future targeted disease modifying drugs for Alzheimer's disease. In: Recent patents on CNS drug discovery. Band 6, Nummer 1, Januar 2011, S. 65–76, ISSN 1574-8898. PMID 21073430. (Review).